# STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

> **NCT00088101** · PHASE1 · COMPLETED · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 42 (—)

## Conditions studied

- Hematological Malignancies
- Leukemia
- Lymphoma
- Metastatic or Unresectable Solid Tumors

## Interventions

- **DRUG:** STA-5312

## Key facts

- **NCT ID:** NCT00088101
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 42 (—)
- **Last updated:** 2008-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088101, "STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00088101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*